{"url_path":"/sec/cnta/8-k/2026-06-24/item-1-02","section_key":"item-1-02","section_title":"Item 1.02 Termination of a Material Definitive Agreement.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-24","source_url":"https://www.sec.gov/Archives/edgar/data/1847903/0001193125-26-280337-index.html","accession_number":"0001193125-26-280337","cik":"0001847903","ticker":"CNTA","issuer_name":"Centessa Pharmaceuticals plc","edgar_url":"https://www.sec.gov/Archives/edgar/data/1847903/0001193125-26-280337-index.html","primary_entity_key":"0001847903","primary_entity_name":"Centessa Pharmaceuticals plc"},"word_count":92,"has_tables":true,"body_markdown":"Item 1.02\n\nTermination of a Material Definitive Agreement.\n\nOn June 24, 2026, in connection with the Acquisition (as defined below), Centessa Pharmaceuticals plc, a public limited company registered in England and Wales (“Centessa” or the “Company”) repaid in full all indebtedness, liabilities and other obligations under, and terminated the Loan and Security Agreement, dated as of December 30, 2024, by and among Centessa Pharmaceuticals Holdings, Inc., Centessa Biosciences, Inc. and Centessa Pharmaceuticals LLC, Oxford Finance LLC (as collateral agent and a lender), and the other lenders from time to time party thereto."}